Insider Files Rule 144 to Sell 12,500 Enliven Therapeutics Shares

Rhea-AI Filing Summary

Form 144 notice for proposed resale by an affiliate. The filing reports a planned sale of 12,500 common shares through Jefferies LLC (520 Madison Ave, New York) with an aggregate market value of $252,750 and an approximate sale date of 08/18/2025 on Nasdaq. The filing lists total shares outstanding as 59,000,000.

The shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics and the filer indicates payment was not applicable. The filer has disclosed recent cash sales of the same issuer during the past three months: 7,500 shares on 06/03/2025 for $150,351.60; 12,500 shares on 06/17/2025 for $277,292.48; and 12,500 shares on 07/17/2025 for $281,517.75. The notice includes the required attestation that the seller is not aware of undisclosed material adverse information.

Positive

• Detailed transaction disclosure including broker, quantity, aggregate value, and approximate sale date
• Recent sale history provided for the past three months with dates and gross proceeds
• Acquisition origin stated (founder shares acquired 09/01/2019 from Enliven Therapeutics)
• Attestation included that the seller is not aware of undisclosed material adverse information

Negative

• Insider selling activity continues with planned sale plus three recent cash sales in the last two months
• Form lacks contextual information on remaining beneficial ownership after these sales (not disclosed in this notice)

Insights

Securities/Insider Transactions Analyst

TL;DR: Routine insider resale disclosure showing continued planned and recent sales of founder shares.

The filing is a standard Rule 144 notice disclosing a single planned resale of 12,500 common shares via Jefferies with an indicated aggregate market value of $252,750 and an expected sale date of 08/18/2025. It also transparently reports three recent cash sales totaling 32,500 shares occurring in June and July 2025 with documented gross proceeds. For investors and compliance teams, the filing confirms the shares originated as founder shares acquired on 09/01/2019 from the issuer. The disclosure meets Rule 144 reporting expectations by providing broker, quantity, acquisition details, and recent sale history.

Corporate Governance / Compliance Expert

TL;DR: Disclosure indicates ongoing insider liquidity but contains no allegations or undisclosed material information.

The notice includes the necessary attestation regarding material nonpublic information and identifies the nature of acquisition as founder shares. Listing prior sales with dates and proceeds improves transparency around insider disposition activity. From a governance perspective, the form documents routine compliance with Rule 144 procedures; it does not, by itself, indicate regulatory or governance concerns beyond ordinary insider selling activity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	12500	252750.00	59000000	08/18/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder Shares	Enliven Therapeutics			12500	09/01/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	06/03/2025	7500	150351.60
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	06/17/2025	12500	277292.48
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	07/17/2025	12500	281517.75

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Who is the seller listed in this Form 144?

The seller is listed as Samuel Kintz at the address shown in the filing.

What securities and quantity are proposed for sale under this Form 144?

The proposed sale is 12,500 common shares to be sold through Jefferies LLC with an aggregate market value of $252,750.

When is the approximate date of the planned sale?

The filing indicates an approximate sale date of 08/18/2025.

Were there recent sales by the same person reported in the filing?

Yes. The filing reports sales of 7,500 shares on 06/03/2025 for $150,351.60, 12,500 shares on 06/17/2025 for $277,292.48, and 12,500 shares on 07/17/2025 for $281,517.75.

How were the shares originally acquired?

The shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics.